Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwrit...
05 Juin 2020 - 10:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex
vivo, today announced the closing of an underwritten public
offering of 6,301,370 shares of its common stock, including the
exercise in full by the underwriters of their option to purchase an
additional 821,917 shares, at the public offering price of $18.25
per share. The gross proceeds raised in the offering, before
underwriting discounts and commissions and estimated expenses of
the offering, were approximately $115 million.
Goldman Sachs & Co. LLC, Jefferies and SVB Leerink acted as
joint book-running managers for the offering.
The shares of common stock were offered by Intellia pursuant to
a shelf registration statement that was previously filed with, and
subsequently declared effective by, the U.S. Securities and
Exchange Commission (SEC). A final prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering was filed with the SEC on June 3, 2020. The final
prospectus supplement and accompanying prospectus relating to the
offering may be obtained from: Goldman Sachs & Co. LLC, by mail
at 200 West Street, New York, NY 10282, Attention: Prospectus
Department, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, by mail at 520
Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity
Syndicate Prospectus Department, by telephone at (877) 547-6340, or
by email at Prospectus_Department@Jefferies.com; or SVB Leerink
LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110,
Attention: Syndicate Department, by telephone at (800) 808-7525,
ext. 6218, or by email at syndicate@svbleerink.com; or by accessing
the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Intellia’s anticipated public offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Intellia’s most recent annual report on Form 10-K and quarterly
report on Form 10-Q filed with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the SEC, including those contained or
incorporated by reference in the final prospectus supplement and
accompanying prospectus related to the public offering filed with
the SEC. Any forward-looking statements contained in this
press release represent Intellia’s views only as of the date hereof
and should not be relied upon as representing its views as of any
subsequent date. Intellia explicitly disclaims any obligation to
update any forward-looking statements, except as required by
law.
Intellia Contacts:
Investors: Lina Li Associate Director Investor
Relations +1 857-706-1612 lina.li@intelliatx.com
Media: Jennifer Mound Smoter Senior Vice
President External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024